Can you spot the difference?
Non-Hodgkin lymphoma (NHL) is a type of blood cancer that starts in the white blood cells, known as lymphocytes, which are a key component of the immune system.1
There are over 90 different types of NHL,1 which can also be classified as indolent (slow growing) or aggressive (fast growing), depending on how quickly the cancer grows.2 Two of the most common types, follicular lymphoma and diffuse large B-cell lymphoma (DLBCL), are very different in how, when and where they develop and how they are managed.
What are the most common subtypes of NHL?
How do cancer cells differ between subtypes?
How quickly does the disease progress?
When are patients usually diagnosed?
What is the course of the disease?
What is the unmet clinical need?
To learn more about lymphoma subtypes, visit
- 1. Lymphoma research foundation. [Internet; cited November 2018]. Available at: https://www.lymphoma.org/aboutlymphoma/
- 2. American Cancer Society. What is Non-Hodgkin Lymphoma. [Internet; cited November 2018]. Available at: https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/what-is-non-hodgkin-lymphoma.html
- 3. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909-18
- 4. Globocan 2018. World fact sheet. [Internet; cited November 2018]. Available at: http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf
- 5. Very Well Health. [Internet; cited November 2018] Available at: https://www.verywellhealth.com/follicular-lymphoma-2252371
- 6. Lymphoma Action. [Internet; cited November 2018]. Available at: https://lymphoma-action.org.uk/sites/default/files/media/documents/2018-06/LYMweb0018DLBCL2016v2.2.pdf.
- 7. Lymphoma Research Foundation. [Internet; cited November 2018]. Available at: http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=6300155 Last accessed September 2016
- 8. Medscape. Diffuse large cell lymphoma. [Internet; cited November 2018]. Available at: http://emedicine.medscape.com/article/202969-overview
- 9. Rovira J et al. Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Ann Hematol. 2015; 94: 803–812.
- 10. Salles GA. Clinical features, prognosis and treatment of follicular lymphoma. Hematology Am Soc Hematol Educ Program 2007; 1:216-225.
- 11. Lymphoma Research Foundation. [Internet; cited November 2018]. Available at: https://www.lymphoma.org/aboutlymphoma/nhl/fl/relapsedfl/
- 12. Maurer, MJ et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014; 32: 1066-73.
- 13. Vaidya R & Witzig TE. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Annals of Oncology 2014; 25:2124–2133.
- 14. Fowler N. Role of Maintenance Rituximab (Rituxan) Therapy In the Treatment of Follicular Lymphoma. Pharmacy and Therapeutics; 2011; 36:590-598
- 15. Dotan E, et al. Impact of rituximab (Rituxan) on the treatment of B-cell non-hodgkin’s lymphoma. Pharmacy and Therapeutics.2010;35:148-57.